1-氰基-L-脯氨酸甲酯 | 367906-51-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-氰基-L-脯氨酸甲酯
• 中文别名: L-脯氨酸,1-氰基-,甲基酯
• 英文名称: (S)-methyl 1-cyanopyrrolidine-2-carboxylate
• 英文别名: methyl (S)-1-cyano-2-pyrrolidinecarboxylate；methyl cyano-L-prolinate；methyl (2S)-1-cyano-2-pyrrolidinecarboxylate；methyl (2S)-1-cyanopyrrolidine-2-carboxylate
• CAS: 367906-51-2
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: HAUJCOYPXFAWIL-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-氰基-L-脯氨酸甲酯 在 sodium hydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 3.25h， 生成
  参考文献：
  名称：

  Structure Reassignment and Synthesis of Jenamidines A₁/A₂, Synthesis of (+)-NP25302, and Formal Synthesis of SB-311009 Analogues

  摘要：

  and C (8-10). Jenamidines A(1)/A(2) (8) were synthesized from activated proline derivative 43 by conversion to 26 in two steps and 50% overall yield. Acylation of 26 with acid chloride 38d gave 39d, which was deprotected with TFA and then mild base to give 8 in 45% yield from 26. (-)-trans-2,5-Dimethylproline ethyl ester (49) was prepared by the enantioselective Michael reaction of ethyl 2-nitropropionate (51) and methyl vinyl ketone (50) using modified dihydroquinine 60 as the catalyst. Further elaboration converted 49 to natural (+)-NP25302 (12). A Wittig reaction of proline NCA ( 76) with ylide 79 gave 72 as a 9/1 E/Z mixture in 27% yield, completing a one-step formal synthesis of SB-311009 analogues.

  DOI：

  10.1021/jo061650+
• 作为产物：
  描述：

  溴化氰 、 L-脯氨酸甲酯 在 三乙胺 作用下， 以 乙醚 为溶剂， 以74%的产率得到1-氰基-L-脯氨酸甲酯
  参考文献：
  名称：

  Iron(iii) catalysed synthesis of unsymmetrical di and trisubstituted ureas – a variation of classical Ritter reaction

  摘要：

  介绍了利用经典Ritter反应合成非对称二取代和三取代脲类化合物的方法，该反应由FeCl3催化。该方案具有重要意义，因为其前体易于获得，反应条件温和，而且在对能够形成稳定碳正离子中间体的醇进行烷基化时，即使是空间位阻较大的基团也能适用。

  DOI：

  10.1039/c2ob06916d

文献信息

• Mechanochemical Preparation of Hydantoins from Amino Esters: Application to the Synthesis of the Antiepileptic Drug Phenytoin
  作者：Laure Konnert、Benjamin Reneaud、Renata Marcia de Figueiredo、Jean-Marc Campagne、Frédéric Lamaty、Jean Martinez、Evelina Colacino

  DOI：10.1021/jo5017629

  日期：2014.11.7

  eco-friendly preparation of 5- and 5,5-disubstituted hydantoins from various amino ester hydrochlorides and potassium cyanate in a planetary ball-mill is described. The one-pot/two-step protocol consisted in the formation of ureido ester intermediates, followed by a base-catalyzed cyclization to hydantoins. This easy-handling mechanochemical methodology was applied to a large variety of α- and β-amino esters

  描述了在行星式球磨机中由各种氨基酯盐酸盐和氰酸钾生态制备5-和5,5-二取代的乙内酰脲的环保方法。一锅/两步方案包括脲基酯中间体的形成，然后碱催化环化成乙内酰脲。这种易于操作的机械化学方法在光滑条件下应用于多种α-和β-氨基酯，可产生高产率的乙内酰脲，而无需纯化步骤。例如，该方法被应用于抗癫痫药苯妥英钠的“绿色”合成，而无需使用任何有害的有机溶剂。
• Cathepsin cysteine protease inhibitors
  申请人：——

  公开号：US20030229226A1

  公开（公告）日：2003-12-11

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K和L的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• <i>N</i> ‐Cyanation of Primary and Secondary Amines with Cyanobenzio‐doxolone (CBX) Reagent
  作者：Zimin Chen、Weiming Yuan

  DOI：10.1002/chem.202102354

  日期：2021.10.25

  An efficient electrophilic N-cyanation of amines with a stable and less-toxic cyanobenziodoxole reagent towards the synthesis of cyanamides is disclosed. This synthetically practicable strategy allows the construction of a wide variety of cyanamides under very mild and simple conditions with a broad functional group compatibility, and showcases a huge potential in late-stage modification of complex

  公开了胺的有效亲电N-氰化与稳定且毒性较低的氰基苯并氧杂环戊烷试剂以合成氰胺。这种综合可行的策略允许在非常温和和简单的条件下构建具有广泛官能团兼容性的各种氰胺，并在复杂分子的后期改性中展现出巨大的潜力。
• Synthesis of Jenamidines A₁/A₂
  作者：Barry B. Snider、Jeremy R. Duvall

  DOI：10.1021/ol0518784

  日期：2005.9.1

  [reaction: see text] Addition of the enolate of tert-butyl acetate to cyanamide methyl ester 17 followed by treatment with LHMDS afforded vinylogous urea 19 in 27% yield. Vinylogous urea 19 was also obtained from 37 and tert-butyl cyanoacetate in 50% yield. Acylation of 19 with acid chloride 31d, followed by hydrolysis of the tert-butyl ester and decarboxylation with 9:1 CH2Cl2/TFA and very mild basic

  [反应：见正文]将乙酸叔丁酯的烯醇盐添加到氰胺甲酯17中，然后用LHMDS处理，得到乙烯基脲19，收率为27％。从37和氰基乙酸叔丁酯也获得了乙烯基脲19，收率为50％。19用酰氯31d酰化，然后叔丁基酯水解并用9：1 CH2Cl2 / TFA脱羧，甲氧基乙酸酯进行非常温和的碱性水解，得到4啶A1 / A2（3），产率为45％。第一次合成证实了我们对Jannamidines A1 / A2结构的重新分配。
• BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF
  申请人：SUZHOU KEEN THERAPEUTICS CO., LTD.

  公开号：WO2023241620A1

  公开（公告）日：2023-12-21

  Provided are compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is cancer.

  本文提供了用于预防或治疗各种病症、紊乱或疾病的化合物、组合物、方法和用途。在某些实施方案中，病症、紊乱或疾病是癌症。